期刊
BRITISH JOURNAL OF PSYCHIATRY
卷 198, 期 5, 页码 351-356出版社
CAMBRIDGE UNIV PRESS
DOI: 10.1192/bjp.bp.110.080044
关键词
-
类别
资金
- Conselho Nacional de Pesquisa Cientifica (CNPq) [554535/2005-0]
- Alzheimer's Association [NIRG-08-90688]
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [02/13633-7]
- Associacifio Beneficente Alzira Denise Hertzog da Silva (ABADHS)
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [02/13633-7] Funding Source: FAPESP
Background Two recent clinical studies support the feasibility of trials to evaluate the disease-modifying properties of lithium in Alzheimer's disease, although no benefits were obtained from short-term treatment. Aims To evaluate the effect of long-term lithium treatment on cognitive and biological outcomes in people with amnestic mild cognitive impairment (aMCI). Method Forty-five participants with aMCI were randomised to receive lithium (0.25-0.5mmol/l) (n=24) or placebo (n = 21) in a 12-month, double-blind trial. Primary outcome measures were the modification of cognitive and functional test scores, and concentrations of cerebrospinal fluid (CSF) biomarkers (amyloid-beta peptide (A beta(42)), total tau (T-tau), phosphorylated-tau) (P-tau). Trial registration: NCT01055392. Results Lithium treatment was associated with a significant decrease in CSF concentrations of P-tau (P=0.03) and better perform-ance on the cognitive subscale of the Alzheimer's Disease Assessment Scale and in attention tasks. Overall tolerability of lithium was good and the adherence rate was 91%. Conclusions The present data support the notion that lithium has disease-modifying properties with potential clinical implications in the prevention of Alzheimer's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据